{
}
UBS has maintained a 'Buy' rating for Orsted, setting a target price of 520 Danish kroner. Analyst Mark Freshney highlighted concerns over further write-downs and delays in the Sunrise Wind project, which are impacting the company's outlook. Orsted, a leading Danish energy firm, primarily focuses on offshore wind farms, contributing significantly to its revenue.
UBS has maintained its "Buy" rating for Orsted, setting a target price of 520 Danish kroner. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
UBS has maintained its 'Buy' rating for Orsted, setting a target price of 520 Danish crowns. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
Analysts have updated their recommendations for several companies, with notable changes including Accor's price target raised to EUR 54 and Legrand upgraded to buy with a target of EUR 125. UBS Group was downgraded to underperform, while Renault's target increased to EUR 68. Other adjustments include Michelin and Ipsen, both seeing target revisions.
UBS has maintained its "Buy" rating for Orsted, setting a target price of 520 Danish crowns. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight-loss injection, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight loss drug, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner. This decision follows positive study results indicating that the high-dose weight loss drug Wegovy leads to greater weight loss compared to lower doses, according to analyst Jo Walton.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish kroner. This decision follows positive study results indicating greater weight loss with the high-dose version of the weight loss drug Wegovy compared to lower doses.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton believes the recent share price reaction to the Phase III results of the CagriSema study is exaggerated, presenting an attractive entry point for investors.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for orsted with target price of 520 kroner
14:06 21.01.2025
ubs maintains buy rating for orsted with target price of 520 kroner
09:19 21.01.2025
ubs upgrades orsted to buy with target price of 520 kroner
09:19 21.01.2025
analysts update recommendations and price targets for major european companies
British Pound Sterling
Danish Krone
Swiss Franc
Euro
Swedish Krona
EXOSENS
Rightmove PLC
Ipsen S.A.
Pluxee N.V.
Accor SA
Legrand SA
Qt Group Oyj
Schneider Electric S.E.
Schindler Holding AG
Compagnie Financière Richemont AG
Fagerhult AB
Icade
Big Yellow Group Plc
AVOLTA N
BT Group plc
Michelin
RENAULT
UBS Group AG
Gecina
Netcompany Group A/S
Covivio
Swedbank AB (publ)
Alstom SA
Ubisoft Entertainment
Capgemini SE
BELIMO Holding AG
Edenred SE
USA
FRA
SWE
CHE
DNK
GBR
Show more
08:38 21.01.2025
ubs upgrades orsted to buy with target price of 520 kroner
08:19 21.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
08:15 21.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
08:04 21.01.2025
ubs maintains buy rating for novo nordisk with positive wegovy study results
17:08 17.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
16:56 17.01.2025
UBS maintains buy rating for Novo Nordisk with target price of 750 crowns
Danish Krone
Novo Nordisk A/S
CHE
DNK
Hubert Dichtl
Thomas Müller
Warren Buffett
Jo Walton
Show more
12:21 16.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: